Summary A mouse monoclonal antibody (IgG2b), 3CIO, was produced against the truncated epidermal growth factor receptor (EGFR), encoded by the (type III) in-frame deletion mutation of 801 nucleotides of EGFR affecting the external domain, known to be expressed in some human glioblastoma. As this mutation newly generates a glycine residue at the fusion point, a 14 amino acid peptide around the fusion junction including this glycine was chemically synthesised. and used for immunisation of (B6 x DBA/2) F1 mice. Flow cytometric analysis showed 3C10 antibody staining of a mouse NIH/3T3 transfectant (ERM5) with the type III EGFR deletion-mutant gene, but not one with wild-type EGFR The antibody immunoprecipitated the truncated EGFR protein with a molecular mass of approximately 140 kDa from ERM5 cells. Immunostaining of glioblastomas revealed binding in the case with the type III EGFR mutation, the five other specimens without the mutation being negative despite overexpression of EGFR in some cases.
Epidermal growth factor receptor (EGFR) gene (protooncogene of v-erbB) is amplified and overexpressed in about 40% of cases of glioblastoma, the major malignant tumour of human brain Wong et al., 1987; Humphrey et al., 1988) . This amplification is frequently correlated with structural rearrangement of EGFR, resulting in in-frame deletion mutations in the extracellular domains (Humphrey et al., 1988 (Humphrey et al., , 1991 Yamazaki et al., 1988 Yamazaki et al., , 1990 Bigner et al., 1990; Wong et al., 1992) . Such deletions in EGFR in glioblastoma have been classified into three types based on the size and location (Humphrey et al., 1991) . Type III has been identified in about 17% of glioblastoma patients (Humphrey et al., 1990) , and is characterised by an 801 bp in-frame deletion, which creates a unique sequence with a glycine residue at the fusion junction between amino acid residues 5 and 274. Since the sequence around the fusion junction is expressed only in glioblastoma cells, it is a potential target for diagnostic and therapeutic approaches. Humphrey et al. (1990) reported the production of polyclonal rabbit antibodies against type III truncated EGFR. In the study, we generated monoclonal antibodies specifically reactive with the fusion junction of this truncated EGFR.
Materials and methods
Cell lines and monoclonal antibody The ERM5 cell line was obtained following transfection of mouse NIH/3T3 fibroblast cells, which do not express wildtype EGFR, with cDNA derived from the human glioma xenograft GL-5 with an 801 bp in-frame type III EGFR deletion (Yamazaki et al., 1990) . NIH/3T3 cells overexpressing exogeneously introduced wild-type human EGFRwere produced as described previously (Yamazaki et al., 1990) and are named EGFR. A431 is a human squamous cell carcinoma cell line overexpressing intact EGFR. EGFR1 mouse monoclonal antibody, which reacts with the external domain of intact EGFR (170 kDa) and blocks the binding of EGF (Waterfield et al., 1982; Carpenter, 1987) , was purchased from Dako, (Glostrup, Denmark).
Synthetic peptides A 14 amino acid peptide corresponding to the fusion junction (amino acid residues 1 -5, glycine, residues 274-280, and terminal cysteine) (named Pep3 according to the report by Humphrey et , 1991 LEEKKGNYVVTDHC) was chemically synthesised with a peptide synthesiser [Applied Biosystems (ABI) 431A, Foster, CA, USA] (Figure 1) , and a portion was coupled to keyhole limplet haemocyanin (KLH). A 17 amino acid peptide also corresponding to the fusion junction without the glycine (LEEKKVCPRNYVVTDHC) was synthesised as a negative control peptide. The amino acid sequences of the synthetic peptides were confirmed using a protein sequencer (ABI 477A).
Production of monoclonal antibody [B6 x DBA/2 (BD)] Fl female mice were immunised intraperitoneally (i.p.) once with 20 ,ug of Pep3 conjugated to KLH, together with Freund's complete adjuvant, and then with 20 ,ug of Pep3 conjugated to KLH with Freund's incomplete adjuvant on day 29. On day 66, 50 jig of Pep3 was administered i.p., and 3 days later, spleen cells were harvested and fused with PAI mouse myeloma cells derived from the NS-1 cell line as described previously (Seto et al., 1982 Reverse transcriptase-polymerase chain reaction (RT-PCR) Total RNA was isolated from the frozen NIH/3T3 transfectants and human glioblastomas by Polytron (Kinematica, Littau, Switzerland) homogenisation in guanidinium isothiocyanate buffer followed by ultracentrifugation through caesium chloride. Single-stranded cDNA was produced using Moloney murine leukaemia virus reverse transcriptase and random primer with hexanucleotides. The single-stranded cDNA was then subjected to PCR using a sense probe (PC 66; CTTCGGGGAGCAGCGATGCGAC) and an antisense probe (PC 77; 1167-1146; GAATGT-GAACGCCTGCGGCAGA) (Sugawa et al., 1990 (Figure 4 ). In contrast, EGFR and A431 cells were stained with EGFR1 antibody, but not with 3C10 antibody. (Figure 9 ). 3C10 antibody stained the glioblastoma of patient 5 (Figure 9a ), but not that of the other patients with or without EGFR amplification. EGFR1 Figure 6 Immunofluorescence staining of ERM5 and EGFR xenografts by 3C10 and EGFR1 antibodies. surrounding glioblastoma were also tested, but they proved negative with both antibodies.
Discussion
We report here the production and characterisation of a monoclonal antibody against a portion of the truncated EGFR encoded by type III internal deletion in-frame (Wikstrand et al., 1993) . More recently, they reported generation of murine monoclonal antibodies against the truncated EGFR from these mice (Wikstrand et al., 1995) .
One of the reasons why we could obtain a monoclonal antibody by immunisation with the peptide alone in the present study may be owing to the choice of BDF1 mice (instead of BALB/c mice), because the mean titre in BDF1 mice was significantly higher than that in (BALB/c x C3H) Fl mice when both were immunise with the same protocol (unpublished observation). Another reason may be that the immunisation peptide consisting of 14-amino acid residue contains a B cell epitope as well as a helper epitope as reported for synthetic immunogens for producing virus neutralising antibody (Palker et al., 1989; Baba et al., 1995 Frequent amplification of EGFR in glioblastomas was initially reported by Libermann et al. (1984) . A subsequent report revealed an amplification incidence of 46% (Ekstrand et al., 1992 (Humphrey et al., 1988) . In the present study, we screened 15 glioblastoma samples by Southern blotting and RT-PCR and found only one case with type III deletion, while five other cases showed amplification of wild-type EGFR. Screening of many more cases, not only with molecular techniques, but also with immunostaining, is required to reveal the incidence in Japanese glioblastoma cases. An important finding regarding mutated EGFR is the recent report of positive staining with polyclonal anti-peptide deletion-mutant EGFR antiserum in five out of 32 nonsmall-cell lung cancers (Garcia de Palazzo et al., 1993) . Wikstrand et al. (1995) also showed three of 11 breast cancers to be stained by their newly produced monoclonal antibody. Molecular biological analysis of these positive lung and breast cancer cases was not conducted, but it is possible that a large variety of tumours reported to have EGFR amplification may also show type III deletion. Immunostaining with our 3C10 antibody should provide valuable information regarding this interesting question.
